Login to Your Account

Biohaven's trigriluzole falls short in phase II/III ataxia trial

By Michael Fitzhugh
Staff Writer

Monday, October 2, 2017

Biohaven Pharmaceutical Holding Co. Ltd.'s trigriluzole, the most advanced candidate from its glutamate modulation platform, failed to outperform a placebo in the treatment of spinocerebellar ataxia (SCA) during a phase II/III study, the largest trial conducted in the rare disorder to date.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription